BCL2 and hematologic disorder: ABT-737 and its orally bioavailable analogue ABT-263 are potent, selective small-molecule inhibitors of Bcl-2 and Bcl-Xl, but not Mcl-1, showing potent clinical activity towards several hematological malignancies [3-5].